The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies. The briefs, filed in the U.S. Court of Appeals for the 5th Circuit, challenge claims by PhRMA, AbbVie and AstraZeneca that the federal law that created the 340B program preempts the state law.

The filings are the latest AHA has made in similar cases in multiple states. The AHA also filed friend-of-the-court briefs regarding the Louisiana cases in February 2024 and December 2023.

The Louisiana Hospital Association, Rural Hospital Coalition, 340B Health and the American Society of Health-System Pharmacists joined AHA in each of the latest filings.

Related News Articles

Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…